227 378

Cited 29 times in

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Authors
 Sang Eun Lee  ;  Seung-Ju Lee  ;  Song-Ee Kim  ;  Kinam Kim  ;  Boyoung Cho  ;  Kyounghwan Roh  ;  Soo-Chan Kim 
Citation
 JCI INSIGHT, Vol.6(2) : e143606, 2021-01 
Journal Title
JCI INSIGHT
Issue Date
2021-01
MeSH
Adolescent ; Adult ; Allografts ; C-Reactive Protein / metabolism ; Child ; Collagen Type VII / genetics ; Cord Blood Stem Cell Transplantation / adverse effects ; Cord Blood Stem Cell Transplantation / methods ; Epidermolysis Bullosa Dystrophica / genetics ; Epidermolysis Bullosa Dystrophica / pathology ; Epidermolysis Bullosa Dystrophica / therapy* ; Female ; Genes, Recessive ; Humans ; Infusions, Intravenous ; Male ; Mesenchymal Stem Cell Transplantation / adverse effects ; Mesenchymal Stem Cell Transplantation / methods* ; Middle Aged ; Mutation ; Pain Measurement ; Pruritus / therapy ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Keywords
Clinical Trials ; Dermatology ; Genetic diseases ; Skin ; Stem cell transplantation
Abstract
BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen [C7]). In this phase I/IIa trial, we evaluated the safety and possible clinical efficacy of intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in patients with RDEB.METHODSFour adult and two pediatric patients with RDEB were treated with 3 intravenous injections of hUCB-MSCs (1 × 106 to 3 × 106 cells/kg) every 2 weeks and followed up for 8-24 months after treatment. The primary endpoint was safety. Secondary endpoints related to efficacy included clinical parameters, such as disease severity score, wound assessment, itch and pain score, and quality of life. C7 expression levels and inflammatory infiltrates in the skin, as well as serum levels of inflammatory markers and neuropeptides, were also assessed.RESULTSIntravenous hUCB-MSC infusions were well tolerated, without serious adverse events. Improvements in the Birmingham Epidermolysis Bullosa Severity Score, body surface area involvement, blister counts, pain, pruritus, and quality of life were observed with maximal effects at 56-112 days after treatment. hUCB-MSC administration induced M2 macrophage polarization and reduced mast cell infiltration in RDEB skin. Serum levels of substance P were decreased after therapy. Increased C7 expression was observed at the dermoepidermal junction in 1 of 6 patients at day 56.CONCLUSIONTo the best of our knowledge, this is the first clinical trial of systemic administration of allogeneic hUCB-MSCs in patients with RDEB, demonstrating safety and transient clinical benefits.TRIAL REGISTRATIONClinicalTrials.gov NCT04520022.FUNDINGThis work was supported by Daewoong Pharmaceutical Co. Ltd. and Kangstem Biotech Co. Ltd.
Files in This Item:
T202102888.pdf Download
DOI
10.1172/jci.insight.143606
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Chan(김수찬) ORCID logo https://orcid.org/0000-0002-2327-4755
Lee, Sang Eun(이상은) ORCID logo https://orcid.org/0000-0003-4720-9955
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184338
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links